Changes in Beneficial Ownership · 4
Celcuity Inc.
CELCNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-10052026_091004.xml
Filing details
- Report period
- 2026-10-01
- Issuer
- Celcuity Inc.
- Issuer CIK
- 0001603454
- Trading symbol
- CELC
Reporting owner 1
- Name
- GRYSKA DAVID W
- Reporting owner CIK
- 0001202335
- Relationship
- Director
- Address
- 2800 CAMPUS DRIVE, SUITE 140, MINNEAPOLIS, MN, 55441
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-01 | A · Form 4 | 893[F1] | A | 0 | 893 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Represents restricted stock units that will vest upon the earlier of (i) the 2027 annual meeting of stockholders of Celcuity Inc. or (ii) April 30, 2027.↩ 1
Signature 1
- Signed
- /s/ Griffin D. Foster as Attorney-in-Fact for David W. Gryska
- Date
- 2026-10-05
Company context
Celcuity is a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, for the treatment of patients with HR+/HER2- ABC. Data from this trial is the basis for FDA approval of REVTORPYK for use in adult patients with HR+/HER2- ABC without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of the VIKTORIA-1 study have been released. Our Phase 3 clinical trial, VIKTORIA-2, is an ongoing trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib in combination with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib in combination with palbociclib and letrozole as first-line treatment for patients w
Current securities
Recent company filings
- 3 filingOct 5, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 2, 2026
- Regulation FD Disclosure · Other EventsSep 30, 2026
- Regulation FD Disclosure · Other EventsAug 26, 2026
- 4 filingAug 18, 2026